Scinai Regains Nasdaq Compliance After 19 Business Days
News related to:Scinai Immunotherapeutics Ltd · 2 min read
JERUSALEM, Sept. 21, 2026 /CourierPR/ -- Scinai Immunotherapeutics Ltd., a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), has regained compliance with Nasdaq's minimum bid price requirement after a period of regulatory scrutiny. The company received confirmation from Nasdaq Listing Qualifications on September 18, 2026, that its American Depositary Shares (ADSs) had maintained a bid price of at least $1.00 for 19 consecutive business days, starting from August 21, 2026, through September 17, 2026.
This development marks a significant milestone for the company, as it had previously faced Nasdaq's notice on March 12, 2026, due to its ADSs failing to meet the $1.00 minimum bid price for 30 consecutive business days.
Reichman further emphasized that the resolution of this matter will allow the company to focus on its core business activities, including the commercial execution of its biopharmaceutical services and the disciplined advancement of its NanoAb programs. Scinai Immunotherapeutics is dedicated to developing innovative immunology therapies and operates a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies. The company's NanoAb platform is a key focus, developed through research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.
The company's CDMO subsidiary, Scinai Biopharma Services Ltd., operates facilities in Jerusalem and Yavne, Israel, offering development and manufacturing services to the biotech and pharmaceutical industries. The company's commitment to maintaining compliance with Nasdaq listing requirements is evident in its proactive engagement with regulatory bodies and its continued efforts to ensure the financial health of its shares.
The company's NanoAb platform is a significant part of its research and development efforts, leveraging advanced technologies to develop innovative immunology therapies. This platform is part of a broader strategy to enhance the company's position in the biopharmaceutical market and to provide robust services to its CDMO clients. The resolution of the Nasdaq compliance issue is expected to bolster investor confidence and support the company's ongoing growth and development initiatives.